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Introduction
Vasopressin has been recognized as an important neuropeptide involved in water conservation (Acher, 1993) and pituitary adrenocorticotropic hormone secretion (Antoni, 1984; Rivier et al., 1984) . The peptide is also recognized as a neurotransmitter or neuromodulator to modulate diverse brain functions such as memory and behavior (De Wied et al., 1991; Drago et al., 1997; Bielsky et al., 2005) , fever (Wilkinson and Kasting, 1987) and central cardiovascular regulation (Milutinovic et al., 2006) . Previously, we reported that the centrally administered vasopressin elevated plasma noradrenaline and adrenaline and this elevation was attenuated by centrally administered indomethacin, an inhibitor of cyclooxygenase, and also abolished by bilateral adrenalectomy (Okada et al., 2003) . These results suggest that the brain vasopressin activates the central adrenomedullary outflow by the brain cyclooxygenase-mediated mechanisms in rats.
Recently, we reported that the vasopressin-induced elevation of plasma catecholamines is mediated by the brain phospholipase C-and diacylglycerol-mediated mechanisms in rats (Shimizu et al., 2004) . Phospholipase C cleaves the phosphodiester bond of membrane phospholipids, resulting the formation of diacylglycerol (Rebecchi and Pentyala, 2000) . Diacylglycerol can be hydrolyzed by diacylglycerol lipase, which is more selective for the sn-1 over the sn-2 position of diacylglycerol (Bisogno et al., 2003) , to produce 2-arachidonoyl-sn-glycerol (Konrad et al., 1994; Stella et al., 1997; Bisogno et al., 2003; Gauthier et al., 2005; Tang et al. 1994 ; Karlsson et al., 1997; Dinh et al., 2002; Tang et al. 2006 ).
2-Arachidonoyl-sn-glycerol has been recognized as a major endocannabinoid for the brain cannabinoid CB receptors (Sugiura et al., 1995; Sugiura and Waku, 2000; De Petrocellis et al., 2004) . Endocannabinoids such as 2-arachidonoyl-snglycerol and anandamide have been shown to have regulatory effects on the sympathetic nervous system (Ishac et al., 1996; Seagard et al., 2004; Brozoski et al., 2005) , in addition to a wide range of central effects including pain processing (Hohmann et al., 2005) , neuroprotection (Melis et al., 2006; Kreitzer and Malenka, 2007) , depression (Gobbi et al., 2005) and neuroendocrine secretion .
In the present study, therefore, we pharmacologically examined (1) a role of the brain 2-arachidonoyl-sn-glycerol as a precursor of arachidonic acid in the centrally administered vasopressin-induced elevation of plasma catecholamines.
Furthermore, we examined (2) a regulatory role of 2-arachidonoyl-sn-glycerol as an endocannabinoid on the vasopressin-induced response in rats. 
Materials and methods

Experimental procedures
Male Wistar rats weighing about 350 g were maintained in an air-conditioned room at 22-24°C under a constant day-night rhythm for more than 2 weeks and given food (laboratory chow, CE-2; Clea Japan, Hamamatsu, Japan) and water ad libitum.
Under urethane anesthesia (1.2 g/kg, i.p.), the femoral vein was cannulated for infusion of saline (1.2 ml/h), and the femoral artery was cannulated for collecting blood samples.
After these procedures, the animal was placed in a stereotaxic apparatus, as shown in our previous papers (Yokotani et al., 1995; Shimizu et al., 2004) . The skull was drilled for intracerebroventricular administration of test substances using stainless-steel cannula (0.3 mm outer diameter). The stereotaxic coordinates of the tip of cannula were as follows (in mm): AP -0.8, L 1.5, V 4.0 (AP, anterior from the bregma; L, lateral from the midline; V, below the surface of the brain), according to the rat brain atlas (Paxinos and Watson, 1986) . Three hours were allowed to elapse before the start of each experiment. All experiments were conducted in compliance with the guiding principles for the care and use of laboratory animals approved by the Kochi University.
Measurement of plasma catecholamines
Blood samples (250 l) were collected through an arterial catheter and were preserved on ice during experiments. Plasma was prepared immediately after the final sampling.
Catecholamines in the plasma were extracted by the method of Anton and Sayre (1962) with a slight modification and were assayed electrochemically with high performance liquid chromatography (HPLC) (Shimizu et al., 2004) . Briefly, after centrifugation, the plasma (100 l) was transferred to a centrifuge tube containing 30 mg of activated alumina, 2 ml of double deionized water, 1 ml of 1.5 M Tris Buffer (pH 8.6) containing 0.1 M disodium EDTA and 1 ng of 3,4-8 dihydroxybenzylamine as an internal standard. The tube was shaken for 10 min and the alumina was washed three times with 4 ml of ice-cold double deionized water. Then, catecholamines adsorbed onto the alumina were eluted with 300 l of 4% acetic acid containing 0.1 mM disodium EDTA. A pump (EP-300: Eicom, Kyoto, Japan), a sample injector (Model-231XL; Gilson, Villiers-le-Bel, France) and an electrochemical detector (ECD-300: Eicom) equipped with a graphite electrode were used with HPLC. Analytical conditions were as follows: detector, +450 mV potential against a Ag/AgCl reference electrode; column, Eicompack CA-50DS, 2.1 x 150 mm (Eicom); mobile phase, 0.1 M NaH 2 PO 4 -Na 2 HPO 4 buffer (pH 6.0) containing 50 mg/l disodium EDTA, 0.75 g/l sodium 1-octanesulfonate and 15% methanol at a flow of 0.18 ml/min; injection volume, 40 l. The amount of catecholamines in each sample was calculated using the peak height ratio relative to that of 3,4-dihydroxybenzylamine. By this assay, coefficients of variation for intra-and interassay were 3.0% and 3.7% respectively, and 0.5 pg of noradrenaline and adrenaline was accurately determined.
Treatment of data and statistics
All values are expressed as the means±S.E.M. The data were analyzed by repeated-measure analysis of variance (ANOVA), followed by post-hoc analysis with the Bonferroni method (Figs. 1, 3 and 4). When only two means were compared, an unpaired Student's t-test was used (Fig. 2) . P values less than 0.05 were taken to indicate statistical significance. (Fig. 1B) .
Effect of MAFP (an inhibitor of monoacylglycerol lipase) on the centrally administered 2-arachidonoyl-sn-glycerolinduced elevation of plasma catecholamines
Treatments with vehicle-1 (2.5 l DMF/animal, i.c.v.) and vehicle-2 (2.5 l DMF/animal, i.c.v.) had no effect on the basal plasma levels of noradrenaline and adrenaline ( (Fig. 3B) .
Effect of WIN 55212-2 (an agonist of cannabinoid CB receptors) on the centrally administered vasopressin-induced elevation of plasma catecholamines
Treatments with vehicle-1 (2.5 l DMF/animal, i.c.v.) and vehicle-2 (10 l saline/animal, i.c.v.) had no effect on the basal plasma levels of noradrenaline and adrenaline (Fig. 4) .
Pretreatment with WIN 55212-2 [470 nmol (250 g)/animal, i.c.v.] also had no effect on the basal plasma levels of both catecholamines (Fig. 4) . (Fig. 4) .
Intravenous pretreatment of WIN 55212-2 [470 nmol (250 g)/animal] had no effect on the vasopressin-induced elevation of both catecholamines (data not shown).
Discussion
2-Arachidonoyl-sn-glycerol is formed from arachidonic acid-enriched membrane phospholipids through phospholipase Cand diacylglycerol lipase-mediated mechanisms (Stella et al., 1997; Gauthier et al., 2005; Tang et al. 2006) . Diacylglycerol lipase overexpression in mouse neuroblastoma increased basal 2-arachidonoyl-sn-glycerol levels and this effect was accompanied by enhanced utilization of 1-stearoyl,2-arachidonoyl-sn-glycerol (a precursor of 2-arachidonoyl-snglycerol) (Jung et al., 2007) . RHC-80267 has been shown to selectively inhibit diacylglycerol lipase activity in human adrenal glomerulosa cells and rat thyroid lobes (Levasseur et al., 1984; Natarajan et al., 1988) , and also to inhibit 2-arachidonoyl-sn-glycerol release in rat brain neurons and bovine coronary endothelial cells (Stella et al., 1997; Gauthier et al., 2005) . In the first experiment, we examined the effect of RHC-80267 on the centrally administered vasopressin-induced elevation of plasma noradrenaline and adrenaline. The reagent effectively reduced the vasopressininduced response, suggesting that 2-arachidonoyl-sn-glycerol generated from diacylglycerol by diacylglycerol lipase is involved in the vasopressin-induced activation of the central adrenomedullary outflow in rats.
2-Arachidonoyl-sn-glycerol can be oxygenated directly by cyclooxygenase to generate glycerol esters of prostaglandins and thromboxane A 2 (Kozak et al., 2000 (Kozak et al., , 2002 , which may serve as a precursor of each prostanoid (Rouzer and Marnett, 2005) .
We previously reported that the sequential actions of the brain cyclooxygenase and thromboxane A 2 synthase are involved in the centrally administered vasopressin-induced elevation of plasma catecholamines in rats (Okada et al., 2003) . However, thromboxane A 2 synthase is far lesser efficient to catalyze 2-arachidonoyl-sn-glycerol-derived glycerol ester of prostaglandin H 2 than prostaglandin H 2 to the corresponding thromboxanes by the sequential action of cyclooxygenase (Kozak et al., 2002) . The evidence suggests that the brain thromboxane A 2 is synthesized from the other pathway than glycerol ester of thromboxane A 2 in the vasopressin-induced activation of adrenomedullary outflow in rats.
2-Arachidonoyl-sn-glycerol can be further hydrolyzed by monoacylglycerol lipase to generate free arachidonic acid (Konrad et al., 1994; Dinh et al., 2002; Tang et al. 2006) , which is further metabolized to prostanoids (prostaglandins and thromboxane A 2 ) by the sequential actions of cyclooxygenase and each prostanoid synthase. In the next experiment, we examined the effect of MAFP on the centrally administered vasopressin-induced elevation of plasma catecholamines. MAFP has been shown to be an inhibitor of phospholipase A 2 or fatty acid amide hydrolase, but it is currently recognized as a very potent (IC 50 value 2-3 nM) inhibitor of 2-arachidonoyl-sn-glycerol hydrolyzing enzymatic activity (Goparaju et al., 1999; Saario et al., 2004) . MAFP has been shown to accumulate endogenous 2-arachidonoyl-snglycerol in rat brain sections by functional autoradiography (Palomaki et al., 2007) . In the present experiment, MAFP effectively attenuated the vasopressin-induced elevation of plasma catecholamines. Since the vasopressin-induced response was not influenced by central pretreatment with mepacrine, an inhibitor of phospholipase A 2 (Shimizu et al., 2004) , the attenuating effect of MAFP on the vasopressin-induced response seems to be due to the inhibition of 2-arachidonoyl-snglycerol hydrolyzing enzymatic activity, thereby reducing arachidonic acid production from 2-arachidonoyl-sn-glycerol.
We further examined the effect of MAFP on the centrally Recently, 2-arachidonoyl-sn-glycerol has been shown to act as an endocannabinoid on cannabinoid CB receptors in the central nervous system (Sugiura et al., 1995; Sugiura and Waku, 2000; De Petrocellis et al., 2004) . So far two types of cannabinoid receptors (CB 1 and CB 2 ) have been identified (Matsuda et al., 1990; Munro et al., 1993) . Cannabinoid CB 1 receptors are expressed predominantly in the central nervous system, whereas cannabinoid CB 2 receptors are present mainly in the immune system (Howlett et al., 2002 (Ross et al., 1999) . AM 251 reverses the cannabinoid CB receptor agonist WIN 55212-2-induced synaptic suppression at hippocampal excitatory synapses on murine pyramidal neurons (Kawamura et al., 2006) and the intra-CA1 injection of WIN 55212-2-induced anxiogeniclike effect in rats (Roohbakhsh et al., 2007) . AM 630 prevents the intrathecally administered CP55940 (a synthetic cannabinoid)-induced analgesia in rat pain models (Romero-
Sandoval and Eisenach, 2007).
In the next experiment, we examined a regulatory role of the brain 2-arachidonoyl-sn-glycerol generated from diacylglycerol as an endocannabinoid on the vasopressin- WIN 55212-2 has been shown to be a non-selective agonist of cannabinoid CB receptors (Felder et al., 1995) . This reagent increases tail-flick reflexes, exerts antihyperalgesic effects and induces hypothermia in rats by central cannabinoid CB 1 receptors (Martin et al., 1998; Fox et al., 2001; Rawls et al., 2002) . In the present experiment, central pretreatment with WIN 55212-2 effectively reduced the vasopressin-induced elevation of plasma catecholamines, but peripheral pretreatment with this reagent had no effect. These results further support a possibility that the brain 2-arachidonoylsn-glycerol generated from diacylglycerol also acts as an endocannabinoid, thereby negatively regulating the vasopressin-induced activation of adrenomedullary outflow in rats.
Cannabinoid has marked effects on peripheral autonomic neurons. Cannabinoid presynaptically inhibits the release of noradrenaline from many postganglionic sympathetic neurons (Malinowska et al., 1997; Niederhoffer and Szabo, 1999) . On the other hand, only a few studies have been carried out to characterize the central effects of cannabinoid on the sympathetic nervous system. Intracisternally administered WIN 55212-2 increased blood pressure and plasma noradrenaline concentration in rabbits and rats, respectively (Niederhoffer and Szabo, 2000; Pfitzer et al., 2004) . Similarly, unilateral microinjection of WIN 55212-2 into the rostral ventrolateral medulla oblongata, a crucial outflow pathway for centrally mediated sympathomodulatory effects, induced sympathoexcitation and hypertension in rats (Padley et al., 2003) . These lines of evidence suggest a possibility that centrally administered cannabinoid elicits sympathetic activation by acting on cardiovascular centers in the medulla oblongata. On the other hand, it is also reported that endocannabinoid released in the nucleus tractus solitarius prolongs baroreflex inhibition of renal sympathetic nerve activity (Seagard et al., 2004; Brozoski et al., 2005) , 
